APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Leber's Hereditary Optic Neuropathy Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Leber's Hereditary Optic Neuropathy Drug Market Outlook and Growth Opportunities 2026

19 December 2025191 pages

Choose your research edition.

Industry ResearchLeber's Hereditary Optic Neuropathy Drug Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Leber's Hereditary Optic Neuropathy Drug Industry Growth and Trends Forecast to 203293 pages · $3,450 USDMarket StructureGlobal Leber's Hereditary Optic Neuropathy Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032183 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Leber's Hereditary Optic Neuropathy Drug Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Leber's Hereditary Optic Neuropathy Drug Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Leber's Hereditary Optic Neuropathy Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Leber's Hereditary Optic Neuropathy Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Leber's Hereditary Optic Neuropathy Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Leber's Hereditary Optic Neuropathy Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Leber's Hereditary Optic Neuropathy Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Leber's Hereditary Optic Neuropathy Drug market include Stealth BioTherapeutics Inc., Spark Therapeutics, Inc., Khondrion BV, Ixchel Pharma, LLC, GenSight Biologics S.A., Biovista Inc. and Alkeus Pharmaceuticals, Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Leber's Hereditary Optic Neuropathy Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Leber's Hereditary Optic Neuropathy Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Leber's Hereditary Optic Neuropathy Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Leber's Hereditary Optic Neuropathy Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Leber's Hereditary Optic Neuropathy Drug Segment by Company

Stealth BioTherapeutics Inc.

Spark Therapeutics, Inc.

Khondrion BV

Ixchel Pharma, LLC

GenSight Biologics S.A.

Biovista Inc.

Alkeus Pharmaceuticals, Inc.

Leber's Hereditary Optic Neuropathy Drug Segment by Type

Elamipretide

KH-176

IXC-201

GS-011

Others

Leber's Hereditary Optic Neuropathy Drug Segment by Application

Hospital

Clinic

Others

Leber's Hereditary Optic Neuropathy Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Leber's Hereditary Optic Neuropathy Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Leber's Hereditary Optic Neuropathy Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Leber's Hereditary Optic Neuropathy Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Leber's Hereditary Optic Neuropathy Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Leber's Hereditary Optic Neuropathy Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Leber's Hereditary Optic Neuropathy Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Leber's Hereditary Optic Neuropathy Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Leber's Hereditary Optic Neuropathy Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Leber's Hereditary Optic Neuropathy Drug industry.

Chapter 3: Detailed analysis of Leber's Hereditary Optic Neuropathy Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Leber's Hereditary Optic Neuropathy Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Leber's Hereditary Optic Neuropathy Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Leber's Hereditary Optic Neuropathy Drug Industry Trends Table 2. Leber's Hereditary Optic Neuropathy Drug Industry Drivers Table 3. Leber's Hereditary Optic Neuropathy Drug Industry Opportunities and Challenges Table 4. Leber's Hereditary Optic Neuropathy Drug Industry Restraints Table 5. Global Leber's Hereditary Optic Neuropathy Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Leber's Hereditary Optic Neuropathy Drug Revenue Share by Company (2021-2026) Table 7. Global Leber's Hereditary Optic Neuropathy Drug Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Leber's Hereditary Optic Neuropathy Drug Sales Volume Share by Company (2021-2026) Table 9. Global Leber's Hereditary Optic Neuropathy Drug Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Leber's Hereditary Optic Neuropathy Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Leber's Hereditary Optic Neuropathy Drug Key Company Manufacturing Base & Headquarters Table 12. Global Leber's Hereditary Optic Neuropathy Drug Company, Product Type & Application Table 13. Global Leber's Hereditary Optic Neuropathy Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Leber's Hereditary Optic Neuropathy Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Elamipretide Table 18. Significant Companies of KH-176 Table 19. Significant Companies of IXC-201 Table 20. Significant Companies of GS-011 Table 21. Significant Companies of Others Table 22. Global Leber's Hereditary Optic Neuropathy Drug Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 23. Global Leber's Hereditary Optic Neuropathy Drug Sales Volume by Type (2021-2026) & (K Units) Table 24. Global Leber's Hereditary Optic Neuropathy Drug Sales Volume by Type (2027-2032) & (K Units) Table 25. Global Leber's Hereditary Optic Neuropathy Drug Sales Volume Share by Type (2021-2026) Table 26. Global Leber's Hereditary Optic Neuropathy Drug Sales Volume Share by Type (2027-2032) Table 27. Global Leber's Hereditary Optic Neuropathy Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Leber's Hereditary Optic Neuropathy Drug Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global Leber's Hereditary Optic Neuropathy Drug Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Type (2021-2026) Table 31. Global Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Hospital Table 33. Significant Companies of Clinic Table 34. Significant Companies of Others Table 35. Global Leber's Hereditary Optic Neuropathy Drug Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global Leber's Hereditary Optic Neuropathy Drug Sales Volume by Application (2021-2026) & (K Units) Table 37. Global Leber's Hereditary Optic Neuropathy Drug Sales Volume by Application (2027-2032) & (K Units) Table 38. Global Leber's Hereditary Optic Neuropathy Drug Sales Volume Share by Application (2021-2026) Table 39. Global Leber's Hereditary Optic Neuropathy Drug Sales Volume Share by Application (2027-2032) Table 40. Global Leber's Hereditary Optic Neuropathy Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Leber's Hereditary Optic Neuropathy Drug Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global Leber's Hereditary Optic Neuropathy Drug Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Application (2021-2026) Table 44. Global Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Application (2027-2032) Table 45. Global Leber's Hereditary Optic Neuropathy Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 46. Global Leber's Hereditary Optic Neuropathy Drug Sales by Region (2021-2026) & (K Units) Table 47. Global Leber's Hereditary Optic Neuropathy Drug Sales Market Share by Region (2021-2026) Table 48. Global Leber's Hereditary Optic Neuropathy Drug Sales by Region (2027-2032) & (K Units) Table 49. Global Leber's Hereditary Optic Neuropathy Drug Sales Market Share by Region (2027-2032) Table 50. Global Leber's Hereditary Optic Neuropathy Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Leber's Hereditary Optic Neuropathy Drug Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Region (2021-2026) Table 53. Global Leber's Hereditary Optic Neuropathy Drug Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Region (2027-2032) Table 55. Global Leber's Hereditary Optic Neuropathy Drug Market Average Price (US$/Unit) by Region (2021-2026) Table 56. Global Leber's Hereditary Optic Neuropathy Drug Market Average Price (US$/Unit) by Region (2027-2032) Table 57. Global Leber's Hereditary Optic Neuropathy Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. Global Leber's Hereditary Optic Neuropathy Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Leber's Hereditary Optic Neuropathy Drug Sales by Country (2021-2026) & (K Units) Table 60. Global Leber's Hereditary Optic Neuropathy Drug Sales Market Share by Country (2021-2026) Table 61. Global Leber's Hereditary Optic Neuropathy Drug Sales by Country (2027-2032) & (K Units) Table 62. Global Leber's Hereditary Optic Neuropathy Drug Sales Market Share by Country (2027-2032) Table 63. Global Leber's Hereditary Optic Neuropathy Drug Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global Leber's Hereditary Optic Neuropathy Drug Sales Value Market Share by Country (2021-2026) Table 65. Global Leber's Hereditary Optic Neuropathy Drug Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global Leber's Hereditary Optic Neuropathy Drug Sales Value Market Share by Country (2027-2032) Table 67. Stealth BioTherapeutics Inc. Company Information Table 68. Stealth BioTherapeutics Inc. Business Overview Table 69. Stealth BioTherapeutics Inc. Leber's Hereditary Optic Neuropathy Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. Stealth BioTherapeutics Inc. Leber's Hereditary Optic Neuropathy Drug Product Portfolio Table 71. Stealth BioTherapeutics Inc. Recent Development Table 72. Spark Therapeutics, Inc. Company Information Table 73. Spark Therapeutics, Inc. Business Overview Table 74. Spark Therapeutics, Inc. Leber's Hereditary Optic Neuropathy Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Spark Therapeutics, Inc. Leber's Hereditary Optic Neuropathy Drug Product Portfolio Table 76. Spark Therapeutics, Inc. Recent Development Table 77. Khondrion BV Company Information Table 78. Khondrion BV Business Overview Table 79. Khondrion BV Leber's Hereditary Optic Neuropathy Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Khondrion BV Leber's Hereditary Optic Neuropathy Drug Product Portfolio Table 81. Khondrion BV Recent Development Table 82. Ixchel Pharma, LLC Company Information Table 83. Ixchel Pharma, LLC Business Overview Table 84. Ixchel Pharma, LLC Leber's Hereditary Optic Neuropathy Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Ixchel Pharma, LLC Leber's Hereditary Optic Neuropathy Drug Product Portfolio Table 86. Ixchel Pharma, LLC Recent Development Table 87. GenSight Biologics S.A. Company Information Table 88. GenSight Biologics S.A. Business Overview Table 89. GenSight Biologics S.A. Leber's Hereditary Optic Neuropathy Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. GenSight Biologics S.A. Leber's Hereditary Optic Neuropathy Drug Product Portfolio Table 91. GenSight Biologics S.A. Recent Development Table 92. Biovista Inc. Company Information Table 93. Biovista Inc. Business Overview Table 94. Biovista Inc. Leber's Hereditary Optic Neuropathy Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Biovista Inc. Leber's Hereditary Optic Neuropathy Drug Product Portfolio Table 96. Biovista Inc. Recent Development Table 97. Alkeus Pharmaceuticals, Inc. Company Information Table 98. Alkeus Pharmaceuticals, Inc. Business Overview Table 99. Alkeus Pharmaceuticals, Inc. Leber's Hereditary Optic Neuropathy Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Alkeus Pharmaceuticals, Inc. Leber's Hereditary Optic Neuropathy Drug Product Portfolio Table 101. Alkeus Pharmaceuticals, Inc. Recent Development Table 102. Key Raw Materials Table 103. Raw Materials Key Suppliers Table 104. Leber's Hereditary Optic Neuropathy Drug Distributors List Table 105. Leber's Hereditary Optic Neuropathy Drug Customers List Table 106. Research Programs/Design for This Report Table 107. Authors List of This Report Table 108. Secondary Sources Table 109. Primary Sources List of Figures Figure 1. Leber's Hereditary Optic Neuropathy Drug Product Image Figure 2. Global Leber's Hereditary Optic Neuropathy Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Leber's Hereditary Optic Neuropathy Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Leber's Hereditary Optic Neuropathy Drug Sales (2021-2032) & (K Units) Figure 5. Global Leber's Hereditary Optic Neuropathy Drug Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Leber's Hereditary Optic Neuropathy Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Elamipretide Image Figure 10. KH-176 Image Figure 11. IXC-201 Image Figure 12. GS-011 Image Figure 13. Others Image Figure 14. Global Leber's Hereditary Optic Neuropathy Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Leber's Hereditary Optic Neuropathy Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global Leber's Hereditary Optic Neuropathy Drug Sales Volume Share by Type (2021-2032) Figure 17. Global Leber's Hereditary Optic Neuropathy Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Leber's Hereditary Optic Neuropathy Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Type (2021-2032) Figure 20. Hospital Image Figure 21. Clinic Image Figure 22. Others Image Figure 23. Global Leber's Hereditary Optic Neuropathy Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Leber's Hereditary Optic Neuropathy Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global Leber's Hereditary Optic Neuropathy Drug Sales Volume Share by Application (2021-2032) Figure 26. Global Leber's Hereditary Optic Neuropathy Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Leber's Hereditary Optic Neuropathy Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Application (2021-2032) Figure 29. Global Leber's Hereditary Optic Neuropathy Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 30. Global Leber's Hereditary Optic Neuropathy Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global Leber's Hereditary Optic Neuropathy Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America Leber's Hereditary Optic Neuropathy Drug Sales Value (2021-2032) & (US$ Million) Figure 34. North America Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe Leber's Hereditary Optic Neuropathy Drug Sales Value (2021-2032) & (US$ Million) Figure 36. Europe Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific Leber's Hereditary Optic Neuropathy Drug Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America Leber's Hereditary Optic Neuropathy Drug Sales Value (2021-2032) & (US$ Million) Figure 40. South America Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa Leber's Hereditary Optic Neuropathy Drug Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA Leber's Hereditary Optic Neuropathy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada Leber's Hereditary Optic Neuropathy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico Leber's Hereditary Optic Neuropathy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany Leber's Hereditary Optic Neuropathy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France Leber's Hereditary Optic Neuropathy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. Leber's Hereditary Optic Neuropathy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy Leber's Hereditary Optic Neuropathy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain Leber's Hereditary Optic Neuropathy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia Leber's Hereditary Optic Neuropathy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands Leber's Hereditary Optic Neuropathy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries Leber's Hereditary Optic Neuropathy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China Leber's Hereditary Optic Neuropathy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan Leber's Hereditary Optic Neuropathy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea Leber's Hereditary Optic Neuropathy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India Leber's Hereditary Optic Neuropathy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia Leber's Hereditary Optic Neuropathy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia Leber's Hereditary Optic Neuropathy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil Leber's Hereditary Optic Neuropathy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina Leber's Hereditary Optic Neuropathy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile Leber's Hereditary Optic Neuropathy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia Leber's Hereditary Optic Neuropathy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru Leber's Hereditary Optic Neuropathy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Leber's Hereditary Optic Neuropathy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel Leber's Hereditary Optic Neuropathy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE Leber's Hereditary Optic Neuropathy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey Leber's Hereditary Optic Neuropathy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran Leber's Hereditary Optic Neuropathy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt Leber's Hereditary Optic Neuropathy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Leber's Hereditary Optic Neuropathy Drug Value Chain Figure 128. Manufacturing Cost Structure Figure 129. Leber's Hereditary Optic Neuropathy Drug Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • Elamipretide
  • KH-176
  • IXC-201
  • GS-011
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Stealth BioTherapeutics Inc.
  • Spark Therapeutics, Inc.
  • Khondrion BV
  • Ixchel Pharma, LLC
  • GenSight Biologics S.A.
  • Biovista Inc.
  • Alkeus Pharmaceuticals, Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Leber's Hereditary Optic Neuropathy Drug Sales Value (2021-2032)
  4. 1.2.2 Global Leber's Hereditary Optic Neuropathy Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Leber's Hereditary Optic Neuropathy Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Leber's Hereditary Optic Neuropathy Drug Market Dynamics
  1. 2.1 Leber's Hereditary Optic Neuropathy Drug Industry Trends
  2. 2.2 Leber's Hereditary Optic Neuropathy Drug Industry Drivers
  3. 2.3 Leber's Hereditary Optic Neuropathy Drug Industry Opportunities and Challenges
  4. 2.4 Leber's Hereditary Optic Neuropathy Drug Industry Restraints
3 Leber's Hereditary Optic Neuropathy Drug Market by Company
  1. 3.1 Global Leber's Hereditary Optic Neuropathy Drug Company Revenue Ranking in 2025
  2. 3.2 Global Leber's Hereditary Optic Neuropathy Drug Revenue by Company (2021-2026)
  3. 3.3 Global Leber's Hereditary Optic Neuropathy Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Leber's Hereditary Optic Neuropathy Drug Average Price by Company (2021-2026)
  5. 3.5 Global Leber's Hereditary Optic Neuropathy Drug Company Ranking (2024-2026)
  6. 3.6 Global Leber's Hereditary Optic Neuropathy Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Leber's Hereditary Optic Neuropathy Drug Company Product Type and Application
  8. 3.8 Global Leber's Hereditary Optic Neuropathy Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Leber's Hereditary Optic Neuropathy Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Leber's Hereditary Optic Neuropathy Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Leber's Hereditary Optic Neuropathy Drug Market by Type
  1. 4.1 Leber's Hereditary Optic Neuropathy Drug Type Introduction
  2. 4.1.1 Elamipretide
  3. 4.1.2 KH-176
  4. 4.1.3 IXC-201
  5. 4.1.4 GS-011
  6. 4.1.5 Others
  7. 4.2 Global Leber's Hereditary Optic Neuropathy Drug Sales Volume by Type
  8. 4.2.1 Global Leber's Hereditary Optic Neuropathy Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Leber's Hereditary Optic Neuropathy Drug Sales Volume by Type (2021-2032)
  10. 4.2.3 Global Leber's Hereditary Optic Neuropathy Drug Sales Volume Share by Type (2021-2032)
  11. 4.3 Global Leber's Hereditary Optic Neuropathy Drug Sales Value by Type
  12. 4.3.1 Global Leber's Hereditary Optic Neuropathy Drug Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Leber's Hereditary Optic Neuropathy Drug Sales Value by Type (2021-2032)
  14. 4.3.3 Global Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Type (2021-2032)
5 Leber's Hereditary Optic Neuropathy Drug Market by Application
  1. 5.1 Leber's Hereditary Optic Neuropathy Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Leber's Hereditary Optic Neuropathy Drug Sales Volume by Application
  6. 5.2.1 Global Leber's Hereditary Optic Neuropathy Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Leber's Hereditary Optic Neuropathy Drug Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Leber's Hereditary Optic Neuropathy Drug Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Leber's Hereditary Optic Neuropathy Drug Sales Value by Application
  10. 5.3.1 Global Leber's Hereditary Optic Neuropathy Drug Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Leber's Hereditary Optic Neuropathy Drug Sales Value by Application (2021-2032)
  12. 5.3.3 Global Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Application (2021-2032)
6 Leber's Hereditary Optic Neuropathy Drug Regional Sales and Value Analysis
  1. 6.1 Global Leber's Hereditary Optic Neuropathy Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Leber's Hereditary Optic Neuropathy Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Leber's Hereditary Optic Neuropathy Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Leber's Hereditary Optic Neuropathy Drug Sales by Region (2027-2032)
  5. 6.3 Global Leber's Hereditary Optic Neuropathy Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Leber's Hereditary Optic Neuropathy Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Leber's Hereditary Optic Neuropathy Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Leber's Hereditary Optic Neuropathy Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Leber's Hereditary Optic Neuropathy Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Leber's Hereditary Optic Neuropathy Drug Sales Value (2021-2032)
  12. 6.6.2 North America Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Leber's Hereditary Optic Neuropathy Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Leber's Hereditary Optic Neuropathy Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Leber's Hereditary Optic Neuropathy Drug Sales Value (2021-2032)
  21. 6.9.2 South America Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Leber's Hereditary Optic Neuropathy Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Country, 2025 VS 2032
7 Leber's Hereditary Optic Neuropathy Drug Country-level Sales and Value Analysis
  1. 7.1 Global Leber's Hereditary Optic Neuropathy Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Leber's Hereditary Optic Neuropathy Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Leber's Hereditary Optic Neuropathy Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Leber's Hereditary Optic Neuropathy Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Leber's Hereditary Optic Neuropathy Drug Sales by Country (2027-2032)
  6. 7.4 Global Leber's Hereditary Optic Neuropathy Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Leber's Hereditary Optic Neuropathy Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Leber's Hereditary Optic Neuropathy Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Leber's Hereditary Optic Neuropathy Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Leber's Hereditary Optic Neuropathy Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Leber's Hereditary Optic Neuropathy Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Leber's Hereditary Optic Neuropathy Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Leber's Hereditary Optic Neuropathy Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Leber's Hereditary Optic Neuropathy Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Leber's Hereditary Optic Neuropathy Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Leber's Hereditary Optic Neuropathy Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Leber's Hereditary Optic Neuropathy Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Leber's Hereditary Optic Neuropathy Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Leber's Hereditary Optic Neuropathy Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Leber's Hereditary Optic Neuropathy Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Leber's Hereditary Optic Neuropathy Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Leber's Hereditary Optic Neuropathy Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Leber's Hereditary Optic Neuropathy Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Leber's Hereditary Optic Neuropathy Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Leber's Hereditary Optic Neuropathy Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Leber's Hereditary Optic Neuropathy Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Leber's Hereditary Optic Neuropathy Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Leber's Hereditary Optic Neuropathy Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Leber's Hereditary Optic Neuropathy Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Leber's Hereditary Optic Neuropathy Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Leber's Hereditary Optic Neuropathy Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Leber's Hereditary Optic Neuropathy Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Leber's Hereditary Optic Neuropathy Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Leber's Hereditary Optic Neuropathy Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Leber's Hereditary Optic Neuropathy Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Leber's Hereditary Optic Neuropathy Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Leber's Hereditary Optic Neuropathy Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Stealth BioTherapeutics Inc.
  2. 8.1.1 Stealth BioTherapeutics Inc. Company Information
  3. 8.1.2 Stealth BioTherapeutics Inc. Business Overview
  4. 8.1.3 Stealth BioTherapeutics Inc. Leber's Hereditary Optic Neuropathy Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Stealth BioTherapeutics Inc. Leber's Hereditary Optic Neuropathy Drug Product Portfolio
  6. 8.1.5 Stealth BioTherapeutics Inc. Recent Developments
  7. 8.2 Spark Therapeutics, Inc.
  8. 8.2.1 Spark Therapeutics, Inc. Company Information
  9. 8.2.2 Spark Therapeutics, Inc. Business Overview
  10. 8.2.3 Spark Therapeutics, Inc. Leber's Hereditary Optic Neuropathy Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Spark Therapeutics, Inc. Leber's Hereditary Optic Neuropathy Drug Product Portfolio
  12. 8.2.5 Spark Therapeutics, Inc. Recent Developments
  13. 8.3 Khondrion BV
  14. 8.3.1 Khondrion BV Company Information
  15. 8.3.2 Khondrion BV Business Overview
  16. 8.3.3 Khondrion BV Leber's Hereditary Optic Neuropathy Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Khondrion BV Leber's Hereditary Optic Neuropathy Drug Product Portfolio
  18. 8.3.5 Khondrion BV Recent Developments
  19. 8.4 Ixchel Pharma, LLC
  20. 8.4.1 Ixchel Pharma, LLC Company Information
  21. 8.4.2 Ixchel Pharma, LLC Business Overview
  22. 8.4.3 Ixchel Pharma, LLC Leber's Hereditary Optic Neuropathy Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Ixchel Pharma, LLC Leber's Hereditary Optic Neuropathy Drug Product Portfolio
  24. 8.4.5 Ixchel Pharma, LLC Recent Developments
  25. 8.5 GenSight Biologics S.A.
  26. 8.5.1 GenSight Biologics S.A. Company Information
  27. 8.5.2 GenSight Biologics S.A. Business Overview
  28. 8.5.3 GenSight Biologics S.A. Leber's Hereditary Optic Neuropathy Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 GenSight Biologics S.A. Leber's Hereditary Optic Neuropathy Drug Product Portfolio
  30. 8.5.5 GenSight Biologics S.A. Recent Developments
  31. 8.6 Biovista Inc.
  32. 8.6.1 Biovista Inc. Company Information
  33. 8.6.2 Biovista Inc. Business Overview
  34. 8.6.3 Biovista Inc. Leber's Hereditary Optic Neuropathy Drug Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Biovista Inc. Leber's Hereditary Optic Neuropathy Drug Product Portfolio
  36. 8.6.5 Biovista Inc. Recent Developments
  37. 8.7 Alkeus Pharmaceuticals, Inc.
  38. 8.7.1 Alkeus Pharmaceuticals, Inc. Company Information
  39. 8.7.2 Alkeus Pharmaceuticals, Inc. Business Overview
  40. 8.7.3 Alkeus Pharmaceuticals, Inc. Leber's Hereditary Optic Neuropathy Drug Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Alkeus Pharmaceuticals, Inc. Leber's Hereditary Optic Neuropathy Drug Product Portfolio
  42. 8.7.5 Alkeus Pharmaceuticals, Inc. Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Leber's Hereditary Optic Neuropathy Drug Value Chain Analysis
  2. 9.1.1 Leber's Hereditary Optic Neuropathy Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Leber's Hereditary Optic Neuropathy Drug Sales Mode & Process
  6. 9.2 Leber's Hereditary Optic Neuropathy Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Leber's Hereditary Optic Neuropathy Drug Distributors
  9. 9.2.3 Leber's Hereditary Optic Neuropathy Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst